PharmaEngine Market Cap ($248.18 Million)
Market Cap & Net Worth: PharmaEngine (4162)
PharmaEngine market cap. PharmaEngine (TWO:4162) has a market capitalization of $248.18 Million (NT$7.88 Billion) as of November 5, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #15479 globally and #683 in its home market, demonstrating a -0.54% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmaEngine's stock price NT$55.60 by its total outstanding shares 141677000 (141.68 Million). Also see PharmaEngine (4162) cash conversion ratio for how efficiently the company converts equity into cash flow.
PharmaEngine Market Cap History (2015–2026)
PharmaEngine market cap history from 2015 to 2026. Data shows change from $629.29 Million to $248.18 Million (-7.23% CAGR). Check 4162 share price today for real-time trading data and today's change.
PharmaEngine Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmaEngine's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of PharmaEngine to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.16x
PharmaEngine's market cap is 0.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.23x
PharmaEngine's market cap is 0.23 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $629.29 Million | $507.24 Million | $394.02 Million | 1.24x | 1.60x |
| 2016 | $573.98 Million | $1.13 Billion | $689.62 Million | 0.51x | 0.83x |
| 2017 | $584.01 Million | $853.68 Million | $387.06 Million | 0.68x | 1.51x |
| 2018 | $439.37 Million | $293.43 Million | $129.36 Million | 1.50x | 3.40x |
| 2019 | $270.03 Million | $314.04 Million | $42.55 Million | 0.86x | 6.35x |
| 2020 | $229.86 Million | $1.06 Billion | $604.28 Million | 0.22x | 0.38x |
| 2021 | $300.95 Million | $654.84 Million | $426.03 Million | 0.46x | 0.71x |
| 2022 | $534.67 Million | $654.38 Million | $318.78 Million | 0.82x | 1.68x |
| 2023 | $462.64 Million | $767.67 Million | $274.65 Million | 0.60x | 1.68x |
| 2024 | $403.06 Million | $2.52 Billion | $1.75 Billion | 0.16x | 0.23x |
Competitor Companies of 4162 by Market Capitalization
Companies near PharmaEngine in the global market cap rankings as of November 5, 2026. Also see PharmaEngine (4162) total assets for a full breakdown of the balance sheet.
Key companies related to PharmaEngine by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of PharmaEngine (2015–2026)
Market capitalization of PharmaEngine from 2015 to today. Between 2015 and today, PharmaEngine's market cap moved from $629.29 Million to $ 248.18 Million, with a yearly change of -7.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$248.18 Million | -21.02% |
| 2025 | NT$314.24 Million | -22.04% |
| 2024 | NT$403.06 Million | -12.88% |
| 2023 | NT$462.64 Million | -13.47% |
| 2022 | NT$534.67 Million | +77.66% |
| 2021 | NT$300.95 Million | +30.93% |
| 2020 | NT$229.86 Million | -14.88% |
| 2019 | NT$270.03 Million | -38.54% |
| 2018 | NT$439.37 Million | -24.77% |
| 2017 | NT$584.01 Million | +1.75% |
| 2016 | NT$573.98 Million | -8.79% |
| 2015 | NT$629.29 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of PharmaEngine was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $248.18 Million USD |
| MoneyControl | $248.18 Million USD |
| MarketWatch | $248.18 Million USD |
| marketcap.company | $248.18 Million USD |
| Reuters | $248.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more